Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

Inclusion criteria

• Willing and able to provide informed consent.
• Males and females of ≥ 18 years of age
• Patient with mild COVID-19 infection having ≥ 1 symptoms.
• Laboratory confirmed Covid-19 infection by Reverse Transcription Polymerase Chain Reaction (RT-PCR) in nasopharyngeal sample (within 72 hours prior to randomization).
• Patient should have at least one pre-existing high-risk feature for developing severe Covid-19 illness.
• Ability to swallow and retain oral medication.
• Male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure.
• Women of childbearing potential should be willing to use a medically acceptable method of contraception.
• Willing to receive telephone calls or have videoconferences with study team personnel.
• Willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.

Exclusion criteria

• Patient with asymptomatic Covid-19 infection.
• Patient who has experienced the onset of any of Covid-19 symptoms > 5 days at the time of randomization.
• Moderate to Severe COVID-19 infection
• Patient with Covid-19 re-infection
• Subjects who are severely immunocompromised
• Subjects with autoimmune diseases
• Patients with any bleeding disorder e.g., hemophilia and von Willebrand disease.
• Current use of other DHODH inhibitors including teriflunomide or leflunomide.
• Patients who are on or immediately require Covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening.
• Patients who have had received one or two doses of vaccine for Covid-19.
• Patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing